PAVmed Inc. entered into a securities purchase agreement for the private placement for gross proceeds of $11,111,110 on March 13, 2023. The company will issue senior secured convertible notes in the transaction. The transaction will include participation from Lucid Diagnostics Inc. and certain accredited investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7507 USD | +9.90% | -0.01% | -46.76% |
Mar. 27 | Cantor Fitzgerald Trims Price Target on Lucid Diagnostics to $3 From $3.80, Maintains Overweight Rating | MT |
Mar. 26 | Transcript : Lucid Diagnostics Inc., Q4 2023 Earnings Call, Mar 26, 2024 |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1.71 USD | -0.58% | -9.04% | 15.78M | ||
0.7507 USD | +9.90% | -0.01% | 32.96M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.76% | 32.96M | |
+72.92% | 12.38B | |
-19.68% | 7.92B | |
+16.20% | 7.2B | |
+6.78% | 5.84B | |
+7.49% | 5.07B | |
+23.97% | 4.53B | |
-21.67% | 3.88B | |
-41.54% | 2.23B | |
+1.24% | 2.02B |
- Stock Market
- Equities
- LUCD Stock
- News Lucid Diagnostics Inc.
- PAVmed Inc. announced that it expects to receive $11.11111 million in funding from Lucid Diagnostics Inc. and others